Lineage Cell Therapeutics, Inc.
New York Stock Exchange ArcaTotal Valuation
Lineage Cell Therapeutics, Inc. carries a market capitalization of 248.03M, placing it among publicly traded companies globally. Its enterprise value stands at 281.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 248.03M |
| Enterprise Value | 281.66M |
Share Statistics
Lineage Cell Therapeutics, Inc. currently has 252.91M shares outstanding.
| Shares Outstanding | 252.91M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 24.14, and the price-to-book ratio stands at 5.44.
| PE Ratio | N/A |
| PS Ratio | 24.14 |
| PB Ratio | 5.44 |
| P/TBV Ratio | 17.87 |
| P/FCF Ratio | -14.12 |
| P/OCF Ratio | -13.26 |
Enterprise Valuation
| EV / Sales | 21.53 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Lineage Cell Therapeutics, Inc. maintains a current ratio of 6.61, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.61 |
| Quick Ratio | 6.44 |
| Debt / Equity | 3.84 |
| Debt / EBITDA | -0.09 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -59.03 |
| Return on Assets (ROA) | -32.75 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -58.22 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Lineage Cell Therapeutics, Inc.'s stock has declined approximately -40.20122% over the past 52 weeks. The 50-day moving average sits at 1.03, while the 200-day moving average is 1.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | -40.20122% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 1.36 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Lineage Cell Therapeutics, Inc. generated 13.08M in revenue and converted that into -32.26M in net income, yielding earnings per share of -0.13. EBITDA reached -26.11M, while operating income came in at -26.85M.
| Revenue | 13.08M |
| Gross Profit | 13.01M |
| Operating Income | -26.85M |
| Pretax Income | -37.38M |
| Net Income | -32.26M |
| EBITDA | -26.11M |
| EBIT | -26.85M |
| Earnings Per Share (EPS) | -0.13 |
Balance Sheet
Lineage Cell Therapeutics, Inc. holds 50.83M in cash and equivalents against 2.30M in total debt, resulting in a net debt position of -37.35M. Total book value stands at 60.92M, with working capital of 44.95M providing operational flexibility.
| Cash & Cash Equivalents | 50.83M |
| Total Debt | 2.30M |
| Net Debt | -37.35M |
| Equity (Book Value) | 60.92M |
| Book Value Per Share | 0.24 |
| Working Capital | 44.95M |
Cash Flow
Lineage Cell Therapeutics, Inc. produced -23.82M in operating cash flow over the past twelve months. After subtracting -574,000.00 in capital expenditures, free cash flow totaled -24.39M - equivalent to -0.10 per share.
| Operating Cash Flow | -23.82M |
| Capital Expenditures | -574,000.00 |
| Free Cash Flow | -24.39M |
| FCF Per Share | -0.10 |
Margins
Lineage Cell Therapeutics, Inc. operates with a gross margin of 99.46, reflecting its pricing power and cost economics. The operating margin of -205.23 and net profit margin of -246.58 provide insight into operational efficiency.
| Gross Margin | 99.46 |
| Operating Margin | -205.23 |
| Pretax Margin | -285.75 |
| Profit Margin | -246.58 |
| EBITDA Margin | -199.58 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -9.73 |
| FCF Yield | -7.08 |
Stock Splits
Lineage Cell Therapeutics, Inc.'s most recent stock split took place on October 31, 1997 with a 1:3 split ratio.
| Last Split Date | 10/31/1997 |
| Split Ratio | 1:3 |
Scores
Lineage Cell Therapeutics, Inc. posts an Altman Z-Score of -6.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.37 |